MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility
June 7, 2016Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth
MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …
Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study
June 7, 2016Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social
Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
The Pharmafocus ASCO round-up
June 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus
As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
FDA approves Allergan hypertension fixed-dose combo, Byvalson
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan
Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
Amgen showcases positive Phase III multiple myeloma drug at ASCO
June 7, 2016Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma
Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
Grünenthal chief executive Eric-Paul Pâques to retire; new CEO named
June 7, 2016CEO, Grünenthal Group, appointment
Germany-based Grünenthal Group on Tuesday named Gabriel Baertschi its chief executive officer effective October 1, 2016. He succeeds Eric-Paul Pâques who will retire at the end of …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
Pivotal avelumab data in Merkel cell carcinoma presented at ASCO
June 6, 2016Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma
New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Weekly Movers: Relypsa, Titan Pharma, Allergan…
June 6, 2016Research and Development, Sales and Marketing Stock, drug trial, research, stock market
The prestigious ASCO meet is underway and results of new drug trials will be a key stock mover over the …
Trial data shows promise for Lilly/MSD combo regimen in lung cancer
June 6, 2016Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship
Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
Bristol-Myers Squibb presents Opdivo data at ASCO
June 6, 2016Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo
Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
June 6, 2016Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
Roche says Phase III trials for giant cell arteritis drug met primary endpoint
June 6, 2016Research and Development, Sales and Marketing Roche, arthritis, drug trial
Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Novo Nordisk presents positive long-term results for Saxenda
June 3, 2016Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss
Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
